194 related articles for article (PubMed ID: 32327176)
1. Adjuvant Chemotherapy.
Hellyer JA; Wakelee HA
Thorac Surg Clin; 2020 May; 30(2):179-185. PubMed ID: 32327176
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
3. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
Santarpia M; Altavilla G; Pitini V; Rosell R
Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
[TBL] [Abstract][Full Text] [Related]
4. [Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)].
Eberhardt W; Fietkau R; Griesinger F; Passlick B; Stuschke M
Onkologie; 2006 Sep; 29 Suppl 2():7-10. PubMed ID: 16974121
[No Abstract] [Full Text] [Related]
5. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
7. Surgical management of early-stage non-small cell lung carcinoma and the present and future roles of adjuvant therapy: a review for the radiation oncologist.
Medford-Davis L; Decamp M; Recht A; Flickinger J; Belani CP; Varlotto J
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1048-57. PubMed ID: 22632771
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
9. Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon.
Passiglia F; Bertaglia V; Reale ML; Delcuratolo MD; Tabbò F; Olmetto E; Capelletto E; Bironzo P; Novello S
Cancer Treat Rev; 2021 Dec; 101():102308. PubMed ID: 34757306
[TBL] [Abstract][Full Text] [Related]
10. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
11. A banner year for immunotherapy and targeted therapy.
Carlisle JW; Ramalingam SS
Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
[No Abstract] [Full Text] [Related]
12. Management of non-small-cell lung cancer: recent developments.
Reck M; Heigener DF; Mok T; Soria JC; Rabe KF
Lancet; 2013 Aug; 382(9893):709-19. PubMed ID: 23972814
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Nagasaka M; Gadgeel SM
Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
[TBL] [Abstract][Full Text] [Related]
14. Management of early-stage non-small-cell lung cancer (NSCLC).
Le Chevalier T
Eur J Cancer; 2011 Sep; 47 Suppl 3():S292-3. PubMed ID: 21943988
[No Abstract] [Full Text] [Related]
15. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Spaans JN; Goss GD
Curr Opin Oncol; 2015 Mar; 27(2):102-7. PubMed ID: 25611026
[TBL] [Abstract][Full Text] [Related]
17. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
Brandt WS; Yan W; Zhou J; Tan KS; Montecalvo J; Park BJ; Adusumilli PS; Huang J; Bott MJ; Rusch VW; Molena D; Travis WD; Kris MG; Chaft JE; Jones DR
J Thorac Cardiovasc Surg; 2019 Feb; 157(2):743-753.e3. PubMed ID: 30415902
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
19. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
Greillier L; Barlesi F
Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
[No Abstract] [Full Text] [Related]
20. Current Landscape of Personalized Therapy.
Horn L; Cass AS
Thorac Surg Clin; 2020 May; 30(2):121-125. PubMed ID: 32327170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
